XINT.STSTOHealthcare · Biotechnology

Xintela AB (publ)

$0.25-4.25%($-0.01)

TickerSpark Score

43/100

Weak

Valuation

Profitability

Growth

Health

Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XINT.ST research report →

52-Week Range12% of range

Low $0.21

Current $0.25

High $0.53

Companywww.xintela.se

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer.

CEO: Evy Lundgren-Åkerlund Assoc.Prof
IPO: 2016
Employees: 21
HQ: Lund, SE

Price Chart

-45.37% · this period

Valuation

Market Cap: $174.43M
P/E: -4.26
P/S: 76.44
P/B: -39.25
EV/EBITDA: -3.28
Div Yield: 0.00%

Profitability

Gross Margin: 86.72%
Op Margin: -2045.79%
Net Margin: -2128.13%
ROE: 284.26%
ROIC: 857.06%

Growth & Income

Revenue: $2.28M · -45.86%
Net Income: $-48,564,000 · -23.92%
EPS: $-0.07 · -2.92%
Op Income: $-46,684,000
FCF YoY: 100.00%

Performance & Tape

52W High: $0.53
52W Low: $0.21
50D MA: $0.25
200D MA: $0.31
Beta: 2.02
Avg Volume: 352.63K

Get TickerSpark's AI analysis on XINT.ST

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime